Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- breast cancer.

Mitch DowsettLucy Suzanne KilburnMothaffar F RimawiC Kent OsborneKatherine Pogue-GeileYuan LiuSamuel A JacobsMelanie FinniganShannon PuhallaAndrew DodsonVera MartinsMaggie Chon U CheangSophie PerryChris HolcombeNick TurnerClaire SwiftJudith M BlissStephen Johnstonnull null

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

High CCNE1 levels were confirmed as a biomarker of resistance to letrozole+palbociclib. Ki67 recovery within 3-9 days of discontinuing palbociclib indicates incomplete suppression of proliferation during the "off" week of its schedule.

Keyphrases

metastatic breast cancer
polycystic ovary syndrome
early breast cancer
signaling pathway
type diabetes
randomized controlled trial
estrogen receptor
endoplasmic reticulum
adipose tissue
metabolic syndrome
study protocol